Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Qnovia","sponsor":"Blue Ledge Capital","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Qnovia, Inc. Raises $17 Million in Series A Funding to Advance Its Inhalable Therapeutics Pipeline","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Qnovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qnovia to Pursue UK Approval for Lead Asset QN-01 in Nicotine Replacement Therapy","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Qnovia","sponsor":"University of Virginia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Qnovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qnovia, Inc. Announces Positive Results from First-In-Human Pharmacokinetic and Safety Study of Lead Asset QN-01, a Prescription Inhaled Smoking Cessation Therapy","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Qnovia

    Menu

    Qnovia

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Qnovia

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Qnovia, Inc. Announces Positive Results from First-In-Human Pharmacokinetic and Safety Study of Lead Asset QN-01, a Prescription Inhaled Smoking Cessation Therapy

              Details:

              QN-01 is a potential breakthrough inhalation small molecule drug therapy, which is currently being investigated for the treatment of smoking cessation.

              Lead Product(s): QN-01

              Therapeutic Area: Psychiatry/Psychology Product Name: QN-01

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Qnovia

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases

              Details:

              The collaboration aims to advance novel inhaled-drug candidates, including QN-05 for the treatment of pneumonia and QN-06 for the treatment of pulmonary infection for individuals exposed to the biodefense agent B. anthracis, the causative agent of anthrax.

              Lead Product(s): QN-05

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: QN-05

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: University of Virginia

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Qnovia

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Qnovia to Pursue UK Approval for Lead Asset QN-01 in Nicotine Replacement Therapy

              Details:

              Gaining MHRA approval would validate the safety and efficacy of QN-01. The company believes it is well-positioned to expand the reach and impact of its NRT therapeutic development efforts by pursuing regulatory approval and gaining license as smoking cessation medicine in UK.

              Lead Product(s): QN-01

              Therapeutic Area: Psychiatry/Psychology Product Name: QN-01

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Qnovia

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Qnovia, Inc. Raises $17 Million in Series A Funding to Advance Its Inhalable Therapeutics Pipeline

              Details:

              The Series A proceeds will be used by Qnovia to advance its NRT drug candidate RespiRx (drud device combination having nicotine) through an IND submission with the FDA and begin human clinical trials in 2023.

              Lead Product(s): Nicotine

              Therapeutic Area: Psychiatry/Psychology Product Name: RespiRx

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Blue Ledge Capital

              Deal Size: $17.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing September 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY